Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 21 of 21 publications.

Jacobson EU, Hicks KA, Carrico J, Purcell DW, Green TA, Mermin JH, Farnham PG. Optimizing HIV prevention efforts to achieve EHE incidence targets. J Acquir Immune Defic Syndr. 2022 Apr;89(4):373-80. doi: 10.1097/QAI.0000000000002885

Montgomery ET, Browne E, Atujuna M, Boeri M, Mansfield C, Sindelo S, Hartmann M, Ndwayana S, Bekker LG, Minnis A. Long-acting injection and implant preferences and trade-offs for HIV prevention among South African male youth. J Acquir Immune Defic Syndr. 2021 Jul 1;87(3):928-36. doi: 10.1097/QAI.0000000000002670

Ali MS, Berencsi K, Marinier K, Deltour N, Perez-Gutthann S, Pedersen L, Rijnbeek P, Lapi F, Simonetti M, Reyes C, Van der Lei J, Sturkenboom M, Prieto-Alhambra D. Comparative cardiovascular safety of strontium ranelate and bisphosphonates: a multi-database study in 5 EU countries by the EU-ADR Alliance. Osteoporos Int. 2020 Dec;31(12):2425-38.

Gilsenan A, Harris D, Reynolds M, McSorley D, Midkiff K, Jackson L, Muldavin B, Kellier-Steele N, Andrews E. Long-term cancer surveillance: results from the Forteo Patient Registry Surveillance Study. Osteoporos Int. 2020 Nov 5;32(4):645-51. doi: 10.1007/s00198-020-05718-0

Berencsi K, Sami A, Ali MS, Marinier K, Deltour N, Perez-Gutthann S, Pedersen L, Rijnbeek P, Van der Lei J, Lapi F, Simonetti M, Reyes C, Sturkenboom MCJM, Prieto-Alhambra D. Impact of risk minimisation measures on the use of strontium ranelate in Europe: a multi-national cohort study in 5 EU countries by the EU-ADR Alliance. Osteoporos Int. 2020 Apr;31(4):721-55. doi: 10.1007/s00198-020-05314-2

Nance RM, Vannappagari V, Smith K, Johannes CB, Calingaert B, Saltus CW, Mayer KH, Whitney BM, Rodriguez B, Moore RD, Eron JJ, Geng E, Mathews WC, Mugavero MJ, Saag MS, Kitahata MM, Delaney JAC, Crane HM. Virologic failure among people living with HIV initiating dolutegravir-based versus other recommended regimens in real-world clinical care settings. J Acquir Immune Defic Syndr. 2019 Aug 15;81(5):572-7. doi: 10.1097/QAI.0000000000002075

Minnis AM, Browne EN, Boeri M, Agot K, van der Straten A, Ahmed K, Weinrib R, Mansfield C. Young women's stated preferences for biomedical HIV prevention: results of a discrete choice experiment in Kenya and South Africa. J Acquir Immune Defic Syndr. 2019 Apr 1;80(4):394-403. doi: 10.1097/QAI.0000000000001945.

Gilsenan A, Harding A, Kellier-Steele N, Harris D, Midkiff K, Andrews E. The Forteo patient registry linkage to multiple state cancer registries: study design and results from the first 8 years. Osteoporos Int. 2018 Oct;29(10):2335-43. doi: 10.1007/s00198-018-4604-8

Khurana N, Yaylali E, Farnham PG, Hicks KA, Allaire BT, Jacobson E, Sansom SL. Impact of improved HIV care and treatment on PrEP effectiveness in the United States, 2016–2020. J Acquir Immune Defic Syndr. 2018 Aug 1;78(4):399-405. doi: 10.1097/QAI.0000000000001707

Hoffman V, Xue F, Gardstein B, Skerry K, Critchlow CW, Enger C. Assessment of off-label use of denosumab 60 mg injection during the early postmarketing period using health insurance claims data. Osteoporos Int. 2016 Apr;27(4):1653-8. doi: 10.1007/s00198-015-3402-9

Andrews EB, Gilsenan AW, Midkiff KD, Harris DH. Comments on Bang et al.: the impact of recombinant parathyroid hormone on malignancies and mortality: 7 years of experience based on nationwide Danish registers. Osteoporos Int. 2015 May;26(5):1663-4. doi: 10.1007/s00198-014-3003-z

Overman RA, Gourlay ML, Deal CL, Farley JF, Brookhart MA, Layton JB. Fracture rate associated with quality metric-based anti-osteoporosis treatment in glucocorticoid-induced osteoporosis. Osteoporos Int. 2015 May;26(5):1515-24. doi: 10.1007/s00198-014-3022-9

Launois R, Le Moine J, Uzzan B, Fiestas Navarette LI, Benamouzig R. Systematic review and bivariate/HSROC random-effect meta-analysis of immunochemical andguaiac-based fecal occult blood tests for colorectal cancer screening. Eur J Gastroenterol Hepatol. 2014 Sep;26(9):978-89. doi: 10.1097/MEG.0000000000000160

Launois R, Fiestas Navarette L, Ethgen O, Le Moine J, Gatsinga R. Health economic value of an innovation: delimiting the scope and framework of future market entry agreements. J Market Access Health Policy. 2014 Jun;2:24988. doi: 10.3402/jmahp.v2.24988

McLellan AR, Wolowacz SE, Zimovetz EA, Beard SM, Lock S, McCrink L, Adekunle F, Roberts D. Fracture liaison services for the evaluation and management of patients with osteoporotic fracture: a cost-effectiveness evaluation based on data collected over 8 years of service provision. Osteoporos Int. 2011 Jul 1;22(7):2083-98.

Tosteson AN, Do TP, Wade SW, Anthony MS, Downs RW. Persistence and switching patterns among women with varied osteoporosis medication histories: 12-month results from POSSIBLE US. Osteoporos Int. 2010 Oct;21(10):1769-80. doi: 10.1007/s00198-009-1133-5

Gutierrez L, Roskell N, Rycroft C, Castellsague J, Beard S, Abeysinghe S, Shannon P, Robbins S, Gitlin M. Economic and clinical burden of non-vertebral non-hip (Nvnh), vertebral and multiple fractures in postmenopausal women in the United Kingdom. Poster presented at IOF World Congress on Osteoporosis & 10th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis; May 2010. Florence, Italy. [abstract] Osteoporos Int. 2010 May 1; 21(Suppl. 1):S96.

Castellsague J, Roskell N, Gutierrez L, Beard S, Rycroft C, Abeysinghe S, Shannon P, Robbins S, Gitlin M. Economic and clinical burden of hip fractures in postmenopausal women in the United Kingdom (UK). Poster presented at the IOF World Congress on Osteoporosis & 10th European Congress on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis; May 2010. Florence, Italy. [abstract] Osteoporos Int. 2010 May 1; 21(Suppl. 1):S95.

Barrett-Connor E, Ensrud K, Tosteson AN, Varon SF, Anthony M, Daizadeh N, Wade S. Design of the POSSIBLE US trade mark study: postmenopausal women's compliance and persistence with osteoporosis medications. Osteoporos Int. 2009 Mar;20(3):463-72. doi: 10.1007/s00198-008-0674-3

Michels KB, Rothman KJ. Update on unethical use of placebos in randomised trials. Bioethics. 2003 Apr;17(2):188-204.

Clarkson TB, Cline JM, Williams JK, Anthony MS. Gonadal hormone substitutes: effects on the cardiovascular system. Osteoporos Int. 1997;7(Suppl 1):543-51.